CPI-300 not checked
Coordination Pharmaceuticals, Inc.
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “CPI-300 will be administered via intravenous infusion on Day 1 of a 14-Day cycle”In the company’s words, NCT04808453 on ClinicalTrials.gov
- Tested for
- Advanced Tumors
- Main trialPhase 1
- “This is a prospective, open-label, single arm, non-randomized study of CPI-300 in patients with advanced tumors. CPI-300 is administered via intravenous infusion using an accelerated titration method followed by a conventional 3 + 3 study design to identify the maximum tolerated dose (MTD).”In the company’s words, NCT04808453 on ClinicalTrials.gov
Other drugs for Advanced Tumors
- PembrolizumabMerck & Co. · Phase 3
- EIK1001Eikon Therapeutics · Phase 2/3
- QL2107Qilu Pharmaceutical · Phase 3
- IFx-Hu2.0TuHURA Biosciences, Inc. · Phase 2/3
- FutibatinibTaiho · Phase 2/3
- MB11mAbxience Research S.L. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | 15 Dec 2023 | Phase I Study of CPI-300 in Patients With Advanced Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026